Pharmaceutical Market Fails to Capture $188 Billion U.S. Revenue and $564 Billion Global Revenue Annually Due to Medication Non-Adherence

Pharmaceutical Market Fails to Capture $188 Billion U.S. Revenue and $564 Billion Global Revenue Annually Due to Medication Non-Adherence PR Newswire NORWALK, Connecticut, Nov. 26, 2012 - Capgemini Consulting and HealthPrize Report Reveals Key Revenue Loss Across 100 Therapeutic Areas Including Chronic Conditions such as – Diabetes, Hypertension and High Cholesterol – and Critical Conditions such as HIV, Cancer and Transplant NORWALK, Connecticut, Nov. 26, 2012 /PRNewswire/ -- Capgemini Consulting, the global strategy and transformation consulting arm of the Capgemini Group, has announced the release of its study conducted with HealthPrize Technologies, "Estimated Annual Pharmaceutical Revenue Loss Due to Medication Non-Adherence." The report provides key insights and analysis on the significant revenue loss to global pharmaceutical companies as a result of medication non-adherence. Based on detailed review and analysis of modern claims-based adherence literature and data, the estimate of revenue lost by the U.S. pharmaceutical industry each year due to non-adherence to medications for chronic disease is $188 billion. Extrapolated to the global pharmaceutical industry, revenue losses are estimated to be $564 billion. This number is significantly higher than the $30 billion global revenue loss often quoted to date from a 2004 study(1), and higher than many pharmaceutical executive estimates.